Atom Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Atom Investors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,274	Closed	-$249K	–	395
2019 Q1	$249K	Buy	+9,274	New	+$217K	0.02%	454

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Atom Investors's ACAD Position: Q2 2019 in Review

Atom Investors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 9,274 shares — an estimated $249K sold.

Atom Investors first reported a position in ACAD in Q1 2019 and held it in 1 quarter. The position peaked at $249K in Q1 2019. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

Atom Investors reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Atom Investors sold 9,274 Acadia Pharmaceuticals shares in Q2 2019, an estimated $249K.
Atom Investors first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 1 quarter.
Atom Investors's Acadia Pharmaceuticals position peaked at $249K in Q1 2019.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Atom Investors's 13F filing for Q2 2019, filed 14 Aug 2019.